PDUFA, FDA Panel Review Dates at Risk with Gov't Shutdown (AMRN) (LGND)

Bloomberg Industries noted today that a shutdown of the federal government could delay some U.S. FDA advisory panel reviews.

The following are upcoming PDUFA dates:

• Alimera (Nadaq: ALIM) and pSivida (Nasdaq: PSDV) Iluvien - October 17th
  
  
• Pfizer (NYSE: PFE) and Ligand's (Nasdaq: LGND) Aprela
  
  
• Antares' (Nasdaq: ATRS) Otrexup
  
  
• Takeda and Lundbeck's vortioxetine

Advisory panel meetings:

• Expanded use of Amarin's (Nasaq: AMRN) Vascepa - October 16th
  
  
• Paladin's Impavido
  
  
• Johnson & Johnson (NYSE: JNJ) and Medivir's simeprevir
  
  
• Gilead's (Nasdaq: GILD) sofosbuvir

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
• VistaGen Therapeutics (VTGN) Reports Positive Results from Phase 2A Pilot Study of PH15
• Kiromic BioPharma (KRBP) Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Trial First Three Patients